Cefepime - Assessment of its need at a tertiary care center

Journal of Clinical Pharmacy and Therapeutics

Volumn 23, Issue 1, 1998, Pages 11-17

  Harbarth, S ^a   Pittet, D ^a   Gabriel, V ^a   Garbino, J ^a   Lew, D ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN DERIVATIVE; FLUCLOXACILLIN; FLUCONAZOLE; GENTAMICIN; METRONIDAZOLE; PENTAMIDINE; PIPERACILLIN PLUS TAZOBACTAM; PYRIMETHAMINE; RIFAMPICIN; SULFADIAZINE; TEICOPLANIN; TETRACYCLINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CELLULITIS; CLINICAL TRIAL; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST CONTROL; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; FEMALE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; SWITZERLAND; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTI-INFECTIVE AGENTS; CEFTAZIDIME; CEPHALOSPORINS; CILASTATIN; CIPROFLOXACIN; COHORT STUDIES; DRUG UTILIZATION REVIEW; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; IMIPENEM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SWITZERLAND; THIENAMYCINS;

EID: 0031849128     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Holmberg SD, Solomon SL, Blake PA. (1987) Health and economic impacts of antimicrobial resistance. Review of Infectious Diseases, 9, 1065-1078.
2. Kunin CM. (1993) Resistance to antimicrobial drugs - a worldwide calamity. Annals of Internal Medicine, 118, 557-561.
3. Joshi N, Milfred D. (1995) The use and misuse of new antibiotics. A perspective. Archives of Internal Medicine, 155, 569-577.
4. Goldmann DA, Weinstein RA, Wenzel RP, et al. (1996) Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. Journal of the American Medical Association, 275, 234-240.
5. Gold HS, Moellering RC, Jr. (1996) Antimicrobial-drug resistance. New England Journal of Medicine, 335, 1445-1453.
6. Jarlier V, Nicolas MH, Fournier G, Philippon A. (1988) Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Review of Infectious Diseases, 10, 867-878.
7. Thomson KS, Sanders WE, Sanders CC. (1994) USA resistance patterns among UTI pathogens. Journal of Antimicrobial Chemotherapy, 33 (Suppl. A), 9-15.
8. Jacobson KL, Cohen SH, Inciardi JF, et al. (1995) The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms. Clinical Infectious Diseases, 21, 1107-1113.
9. Pena C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J. (1995) Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrobial Agents and Chemotherapy, 39, 520-524.
10. Itokazu GS, Quinn JP, Bell-Dixon C, Kahan FM, Weinstein RA. (1996) Antimicrobial resistance rates among aerobic Gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clinical Infectious Diseases, 23, 779-784.
11. Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP. (1994) Therapeutic-class wars - drug promotion in a competitive marketplace. New England Journal of Medicine, 331, 1350-1353.
12. Shorr RI, Greene WL. (1995) A food-borne outbreak of expensive antibiotic use in a community teaching hospital. Journal of the American Medical Association, 273, 1908.
13. Sanders CC. (1993) Cefepime: the next generation? Clinical Infectious Diseases, 17, 369-379.
14. Cunha BA, Gill MV. (1995) Cefepime. Medical Clinics of North America, 79, 721-732.
15. Cordonnier C, Herbrecht R, Pico JL, et al. (1997) Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: A comparative study. Clinical Infectious Diseases, 24, 41-51.
16. Gouin F, Papazian L, Martin C, et al. (1993) A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacirt in the treatment of severe infections in patients in intensive care. Journal of Antimicrobial Chemotherapy, 32 (Suppl. B), 205-214.
17. Saez-Llorens X, Castano E, Garcia R, et al. (1995) Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Antimicrobial Agents and Chemotherapy, 39, 937-940.
18. Schrank JH Jr, Kelly JW, McAllister CK. (1995) Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with Gram-negative bacteremia. Clinics in Infectious Diseases, 20, 56-58.
19. Sharifi R, Geckler R, Childs S. (1996) Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections. American Journal of Medicine, 100, 76-82.
20. McCabe R, Chirurgi V, Farkas SA, Haddow A, Heinz G, Greene S. (1996) A new therapeutic option for the treatment of pneumonia. American Journal of Medicine, 100, 60-67.
21. Neu HG. (1996) Safety of cefepime: a new extended-spectrum parenteral cephalosporin. American Journal of Medicine, 100, 68-75.
22. Marchou B, Michea-Hamzehpour M, Lucain C, Pechere JC. (1987) Development of beta-lactam-resistant Enterobacter cloacae in mice. Journal of Infectious Diseases, 156, 369-373.
23. Johnson CC, Livornese L, Gold MJ, Pitsakis PG, Taylor S, Levson ME. (1995) Activity of cefepime against ceftazidime-resistant Gram-negative bacilli using low and high inocula. Journal of Antimicrobial Chemotherapy, 35, 765-773.
24. Sanders WE Jr, Tenney JH, Kessler RE. (1996) Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clinical Infectious Diseases, 23, 454-461.
25. Anon. (1996) Cefepime (Maxipime) - a new parenteral cephalosporin. Medical Letter, 38, 84-86.
26. Wertheimer AI. (1986) The defined daily dose system (DDD) for drug utilization review. Hospital Pharmacy, 21, 233-241.
27. Pittet D, Safran E, Harbarth S, Rohner P, Auckenthaler R. (1996) Trends and Impact of Gram-Negative Bacteremia. 4th International Conference on the Prevention of Infection 1996. Nice, France: C2-03 (Abstract).
28. Chow JW, Fine MJ, Shlaes DM, et al. (1991) Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Annals of Internal Medicine, 115, 585-590.
29. Burwen DR, Banerjee SN, Gaynes RP. (1994) Ceftazidime resistance among selected nosocomial Gram-negative bacilli in the United States. National nosocomial infections surveillance system. Journal of Infectious Diseases, 170, 1622-1625.
30. Kunin CM. (1985) The responsibility of the infectious disease community for the optimal use of antimicrobial agents. Journal of Infectious Diseases, 151, 388-398.
31. John JF, Fishman N. (1997) Programmatic role of the Infectious Diseases Physician in controlling antimicrobial costs in the hospital. Clinical Infectious Diseases, 24, 471-485.
32. Gentry LO, Rodriguez-Gomez G. (1991) Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects. Antimicrobial Agents and Chemotherapy, 35, 2371-2374.
33. Hoepelman AI, Kieft H, Aoun M, et al. (1993) International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. Journal of Antimicrobial Chemotherapy, 32 (Suppl. B), 175-186.
34. Kieft H, Hoepelman AI, Rozenberg-Arska M, et al. (1994) Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome. Antimicrobial Agents and Chemotherapy, 38, 415-421.